Saccade
Saccade is a YC Fall 2026 (F26) company. Based in San Francisco, CA, USA. Team of 2.
About Saccade
Summary
Saccade builds an early-detection screening tool for Alzheimer's biomarkers, targeting patients at longevity clinics before any cognitive symptoms appear. A patent-pending attachment on a standard VR headset captures eye movement patterns during a 15-minute neurologist-designed assessment, then an ML model scores Alzheimer's risk against those patterns. The tool replaces late-stage symptom-prompted diagnosis, giving clinicians a window to intervene with FDA-approved treatments while they can still slow the disease.
Business model
$10 per unit per month
Go-to-market
Longevity clinics are the initial point of sale and patient access channel, with referrals flowing downstream to neurology and longevity practices based on assessed risk stage.
From the Y Combinator listing
World's Earliest Test for Alzheimer's Biomarkers
Alzheimer's testing today is bottlenecked around the onset of symptoms, when the damage is already done. Current treatments, including the FDA-approved drugs released in 2024, don't reverse the disease; they only slow it down. Earlier detection means earlier intervention. Eye movement changes linked to Alzheimer's surface sooner than any other biomarker, up to 15 years before symptoms appear. We deliver a 15-minute VR assessment delivered to patients in longevity clinics: • Tasks: patients perform visual tasks designed by neurologists to trigger a distinct oculomotor response in people with Alzheimer's or on its path • Hardware: our patent-pending attachment connects to any VR headset on the market and captures these eye movement patterns. • Analysis: the patterns are compared against our ML model to produce a risk analysis. Once classified, patients can access new interventions, such as the FDA-approved drugs. They're also referred to longevity practices, neurology practices or both, depending on their stage of decline. Testing for the earliest biomarkers allows the earliest possible intervention. In some cases, that slows the disease enough that patients outlive the onset of symptoms and never face memory loss in their lifetime.
Facts
- Healthcare / Healthcare -> Consumer Health and Wellness
- San Francisco, CA, USA
- 2
- Active
- Early
Founders (1)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works